Reversing Alzheimer’s: Cancer Drugs Show Promise
Cancer Drugs Show Promise in Reversing Alzheimer’s Disease Signatures in Groundbreaking Study
Table of Contents
Novel Approach Identifies Existing Therapies with Potential to Treat Neurodegenerative Condition
San Francisco, CA – In a significant leap forward for Alzheimer’s research, scientists have identified a combination of two existing cancer drugs that effectively reversed key hallmarks of the disease in a preclinical model. The innovative study, leveraging vast datasets and advanced computational analysis, offers a beacon of hope for millions affected by this devastating neurodegenerative disorder.
The research team, a collaboration between the University of California, San Francisco (UCSF) and the Gladstone Institutes, employed a sophisticated strategy to pinpoint potential Alzheimer’s treatments. They began by analyzing gene expression signatures – the patterns of genes that are turned on or off – in both neurons and glial cells affected by Alzheimer’s disease.These signatures represent the molecular fingerprints of the disease’s progression.
From Big Data to Promising Candidates: A Computational Journey
The researchers then cross-referenced these Alzheimer’s gene expression signatures with the Connectivity Map, a comprehensive database containing the results of gene expression changes induced by thousands of drugs in human cells. This powerful comparison allowed them to identify drugs that could potentially “reverse” the disease’s molecular profile.
“Out of 1,300 drugs, 86 reversed the Alzheimer’s disease gene expression signature in one cell type, and 25 reversed the signature in several cell types in the brain,” explained Yaqiao Li, PhD, the study’s lead author and a former UCSF graduate student now at Gladstone. “But just 10 had already been approved by the FDA for use in humans.”
The investigation didn’t stop there. The team delved into the UC Health Data Warehouse, a repository of anonymized health details from 1.4 million individuals over 65. This crucial step allowed them to examine the real-world impact of these FDA-approved drugs.
“Poring through records housed in the UC Health Data Warehouse… the group found that several of these drugs seemed to have reduced the risk of developing Alzheimer’s disease over time,” the study notes. This real-world data further narrowed the field. ”Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just 5,” Li added. “In particular, the rich data collected by all the UC health centers pointed us straight to the most promising drugs. It’s kind of like a mock clinical trial.”
A Combination Therapy Poised for Primetime
From the top five drug candidates,the researchers selected two cancer drugs for laboratory testing: letrozole,typically used to treat breast cancer,and irinotecan,used for colon and lung cancer. Their hypothesis was that letrozole would benefit neurons, while irinotecan would support glial cells, both critical components of brain health affected by Alzheimer’s.
The team utilized a mouse model engineered to exhibit aggressive Alzheimer’s disease, incorporating multiple genetic mutations associated with the condition. As these mice aged and developed Alzheimer’s-like symptoms,they were treated with either one or both of the selected cancer drugs.The results were striking. The combination therapy demonstrated a remarkable ability to reverse multiple aspects of Alzheimer’s pathology in the animal model. It effectively undid the specific gene expression signatures that had emerged as the disease progressed in both neurons and glia. Furthermore, the treatment significantly reduced the formation of toxic protein clumps, a hallmark of Alzheimer’s, and mitigated brain degeneration. Crucially, the combination therapy also restored memory function in the treated mice.
“It’s so exciting to see the validation of the computational data in a widely used Alzheimer’s mouse model,” said Dr. Fenghua Huang, a senior author on the study. The team is optimistic that this research will soon advance to human clinical trials.
“If completely autonomous data sources, such as single-cell expression data and clinical records, guide us to the same pathways and the same drugs, and then resolve Alzheimer’s in a genetic model, then maybe we’re onto something,” commented dr. Michael Sirota, another senior author. “We’re hopeful this can be swiftly translated into a real solution for millions of patients with Alzheimer’s.”
The study’s findings represent a significant advancement in the search for effective Alzheimer’s treatments, highlighting the power of integrating diverse data sources and repurposing existing medications.Authors: Other UCSF authors include Carlota Pereda Serras, MS, jessica Blumenfeld, Xinyu Tang, PhD, Antara Rao, PhD, Sarah Woldemariam, PhD, Alice Tang, PhD, Tomiko Oskotsky,